UPMC Physician Resources

Archives for Cancer

UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients

PITTSBURGH, July 24, 2014 – The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers from the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter.

The test, available at the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic testing agencies, improved the chances of patients getting the correct initial surgery by 30 percent, according to the study published this month in the Annals of Surgery.

“Before this test, about one in five potential thyroid cancer cases couldn’t be diagnosed without an operation to remove a portion of the thyroid,” said lead author Linwah Yip, M.D., assistant professor of surgery in Pitt’s School of Medicine and UPMC surgical oncologist.  Previously, “if the portion removed during the first surgery came back positive for cancer, a second surgery was needed to remove the rest of the thyroid. The molecular testing panel now bypasses that initial surgery, allowing us to go right to fully removing the cancer with one initial surgery. This reduces risk and stress to the patient, as well as recovery time and costs.”

Cancer in the thyroid, which is located in the “Adam’s apple” area of the neck, is now the fifth most common cancer diagnosed in women.  Thyroid cancer is one of the few cancers that continues to increase in incidence, although the five-year survival rate is 97 percent.

Previously, the most accurate form of testing for thyroid cancer was a fine-needle aspiration biopsy, where a doctor guides a thin needle to the thyroid and removes a small tissue sample for testing. However, in 20 percent of these biopsies, cancer cannot be ruled out. A lobectomy, which is a surgical operation to remove half of the thyroid, is then needed to diagnose or rule-out thyroid cancer. In the case of a postoperative cancer diagnosis, a second surgery is required to remove the rest of the thyroid.

Researchers have identified certain gene mutations that are indicative of an increased likelihood of thyroid cancer, and the molecular testing panel developed at UPMC can be run using the sample collected through the initial, minimally invasive biopsy, rather than a lobectomy. When the panel shows these mutations, a total thyroidectomy is advised.

Dr. Yip and her colleagues followed 671 UPMC patients with suspicious thyroid nodes who received biopsies. Approximately half the biopsy samples were run through the panel, and the other half were not. Patients whose tissue samples were not tested with the panel had a 2.5-fold higher statistically significant likelihood of having an initial lobectomy and then requiring a second operation.

“We’re currently refining the panel by adding tests for more genetic mutations, thereby making it even more accurate,” said co-author Yuri Nikiforov, M.D., Ph.D., professor in the Department of Pathology at Pitt and director of thyroid molecular diagnostics at the UPMC/UPCI Multidisciplinary Thyroid Center. “Thyroid cancer is usually very curable, and we are getting closer to quickly and efficiently identifying and treating all cases of thyroid cancer.”

In 2009, the American Thyroid Association (ATA) revised its guidelines to add that doctors may consider the use of molecular markers when the initial biopsy is inconclusive.

“The ATA is currently revising those guidelines to take into account the latest research, including our findings,” said senior author Sally Carty, M.D., Pitt professor of surgery, co-director of the UPMC/UPCI Multidisciplinary Thyroid Center and recent president of the American Association of Endocrine Surgeons. “The molecular testing panel holds promise for streamlining and eliminating unnecessary surgery not just here but nationwide.”

A previous study led by Dr. Yip showed the panel to be cost-saving when used to help in the diagnosis of thyroid cancer.

Each year, approximately half of the 25,000 patients assessed at UPMC’s Multidisciplinary Thyroid Center are found to have thyroid conditions, and more than 900 thyroid operations are performed by the center’s surgeons. The center aims to provide patients with one-stop evaluation from thyroid experts in a variety of fields, including surgery and endocrinology.

Additional researchers on this study are Laura I. Wharry, M.D., Michaele J. Armstrong, Ph.D., Ari Silbermann, B.S., Kelly L. McCoy, M.D., and Michael T. Stang, M.D., all of the Pitt Department of Surgery; Nobuyuki P. Ohori, M.D., and Marina N. Nikiforov, M.D., all of the Pitt Department of Pathology; Shane O. LeBeau, M.D., Christopher Coyne, M.D., and Steven P. Hodak, M.D., all of the Pitt Department of Endocrinology; Julie E. Bauman, M.D., of the PItt Department of Hematology/Oncology; Jonas T. Johnson, M.D., of the Pitt Department of Otolaryngology; and Mitch E. Tublin, M.D., of the Pitt Department of Radiology.

This study was funded by a grant from UPMC.

Viral Infections, Including Flu, Could Be Inhibited by Naturally Occurring Protein, UPCI Finds

PITTSBURGH, June 12, 2014 – By boosting a protein that naturally exists in our cells, an international team of researchers led by the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, has found a potential way to enhance our ability to sense and inhibit viral infections.The laboratory-based discovery, which could lead to more effective treatments for viruses ranging from hepatitis C to the flu, appears in the June 19 issue of the journal Immunity. The research is supported by the National Institutes of Health.

“Despite remarkable advances in vaccination and treatment, diseases caused by viral infections remain among the leading causes of death worldwide,” said senior author Saumendra N. Sarkar, Ph.D., assistant professor of microbiology and molecular genetics at UPCI. “We need new defenses against viral infections, and our discovery is proving to be a promising avenue for further exploration.”

Dr. Sarkar and his team made the discovery while investigating a protein called oligoadenylate synthetases-like, or OASL, which appears in increased quantities in people with liver cancer caused by the hepatitis C virus.

Hepatitis C, influenza, the childhood respiratory illness RSV, and many other viruses are known as ribonucleic acid (RNA) viruses, which use RNA as their genetic material when they replicate. The OASL protein enhances cells’ ability to detect virus RNA, activating the immune system to sense the virus and inhibit replication.

In laboratory tests, boosting this protein in human cells effectively inhibits viral replication. Conversely, mice that do not have OASL were found to be much more susceptible to viral infections.

The finding is especially notable because it may offer an alternative to interferons, another kind of protein that is made and released by cells in response to viruses. Interferons are used in therapy against some viral infections, including hepatitis C, but are not effective for other RNA viruses, such as influenza. Interferon therapy also has major side effects, and not all patients respond well to treatment.

Dr. Sarkar and his team plan to determine the most efficient way to boost the OASL pathway in patients and are working with pulmonologists to develop and identify funding for a study to evaluate the effect of boosting OASL in people with lung infections.

“The respiratory system is a much easier target to deliver this type of therapy, compared to an organ, such as the liver, so we’ll be starting with infections like RSV,” said Dr. Sarkar. “From there we could branch out to other RNA viruses and perhaps find effective ways to boost our inherent immunity against a broad range of viral infections.”

Additional authors on this study are Jianzhong Zhu, Ph.D., Yugen Zhang, Ph.D., Arundhati Ghosh, Ph.D., Rolanodo A. Cuevas, M.S., Adriana Forero, Ph.D., Madhavi K. Ganapathiraju, Ph.D., Carolyn B. Coyne, Ph.D., all of Pitt; Jayeeta Dhar, Ph.D., and Sailen Barik, Ph.D., both of Cleveland State University; Mikkel Søes Ibsen, M.S., and Rune Hartmann, Ph.D., both of Aarhus University in Denmark; Jonathan Leo Schmid-Burgk, M.S., Tobias Schmidt, M.S., and Veit Hornung, Ph.D., all of the University of Bonn in Germany; and Takashi Fujita, Ph.D., of Kyoto University in Japan.

This research was supported by National Institute of Allergy and Infectious Diseases grant no. AI082673 and UPCI.

Potential Breast Cancer Drug Performs Well in Early Clinical Trials

CHICAGO, June 1, 2014 – A drug previously studied to improve chemotherapy may be effective in treating patients with cancers related to the BRCA 1 or 2 genetic mutations, as well as patients with BRCA-like breast cancers, according to a University of Pittsburgh Cancer Institute (UPCI) clinical trial.

The results of the phase I study were presented today at the 50th annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The drug, veliparib (ABT-888), is a PARP inhibitor, which means it lowers the resistance of cancer cells to treatment by targeting the polymerase (PARP) family of enzymes responsible for a wide variety of cellular processes in cancer cells, particularly DNA repair.

“Cancer cells have increased levels of PARP, which we believe may, in part, lead to resistance to chemotherapies and other cancer treatments,” said Shannon Puhalla, M.D., assistant professor of medicine, University of Pittsburgh School of Medicine, and breast oncologist with UPMC CancerCenter at Magee-Womens Hospital of UPMC. “Tumor cells in patients with BRCA mutations are particularly sensitive to the effects of PARP inhibitors due to underlying DNA repair abnormalities caused by the BRCA mutation. Veliparib can act as personalized medicine for patients with tumors caused by an inherited BRCA mutation, due to this particular sensitivity.”

The study enrolled 60 patients with a BRCA genetic mutation and 28 patients without a mutation. The objectives of the trial included determining how veliparib affected cancer cells and observing how patients responded to the drug.

“We found that veliparib is well-tolerated by patients, with fewer side effects than what can be seen with chemotherapies. In addition, anti-tumor activity was detected in both our BRCA-positive and our BRCA-negative patients,” said Dr. Puhalla.

Dr. Puhalla and a research team at UPCI have been investigating ABT-888 for five years. Their research began in the laboratory and progressed to human clinical trials. Dr. Puhalla currently is leading a phase II clinical trial with ABT-888.

“Many cancer patients with BRCA mutations end up exhausting their treatment options. Veliparib may give them another option.” Dr. Puhalla said.

The study was funded in part by an ASCO career development award Dr. Puhalla received in 2010 and an ASCO translational research professorship received by the late Merrill Egorin, M.D., who co-directed the Molecular Therapeutics and Drug Discovery program at UPCI. This study also is supported by the Pittsburgh-based Frieda G. and Saul F. Shapira BRCA Cancer Research Program and Cancer Fighting Princess.

Pennsylvania Recognizes May as Bladder Cancer Awareness Month

PITTSBURGH, May 20, 2014 The month of May has been officially recognized as Bladder Cancer Awareness Month by the State of Pennsylvania. Resolution #699 was sponsored by Representative Robert Freeman, and overwhelmingly passed by the PA House of Representatives. This recognition by the state of PA aligns with the national efforts of the Bladder Cancer Advocacy Network (BCAN). Marge Coffin, the Lehigh Valley-Central PA Chapter President of the BCAN, worked with Representative Freeman’s office to make the recognition official.

“I believe that Resolution #699 is a positive step forward in our efforts to raise awareness and understanding of this disease,” Coffin says.

In the United States, bladder cancer is the sixth most commonly diagnosed form of cancer and approximately 75,000 will be diagnosed this year. There is little public awareness of the disease, despite the fact that more than 500,000 people are currently living it. The signs and symptoms of bladder cancer can be similar to those of other conditions, which has often led to later diagnoses and poor outcomes. Throughout the month, the BCAN will provide educational materials, host events, and will focus on women and bladder cancer.

For more information about Bladder Cancer Awareness Month, please visit BCAN.org.

Jeffrey Gingrich, MD, from the Department of Urology at UPMC discusses the management and treatment of  bladder cancer in the following video: Neoadjuvant Chemotherapy in the Management of Bladder Cancer.

Maryland Patients Can Now Access UPMC CancerCenter Resources Under New Affiliation with Meritus Health’s John R. Marsh Cancer Center in Hagerstown

PITTSBURGH, May 20, 2014 – Cancer patients in Hagerstown, Md., now have access to UPMC CancerCenter’s world-class clinical care and the latest research under a new affiliation agreement with Meritus Health’s John R. Marsh Cancer Center.

The agreement, effective May 1, allows patients to access the vast resources of the UPMC CancerCenter, including its treatment protocols, clinical trials, provider-to-provider consultations, genetic counseling support services and collaboration in research and survivorship programs.

“We are excited to be able to work with Meritus Health’s John R. Marsh Cancer Center and to offer patients in Maryland access to our vast cancer network. We are proud to be able to offer patients the best in care right in their own communities and this affiliation affirms our commitment to do just that,” said Stanley Marks, M.D., chairman of UPMC CancerCenter, partner with the University of Pittsburgh Cancer Institute.

Clinical and professional staff at Meritus Health’s John R. Marsh Cancer Center also can participate in training and education programs offered through UPMC CancerCenter, the only National Cancer Institute-designated comprehensive cancer center in western Pennsylvania.

“Meritus Health is proud of our John R. Marsh Cancer Center’s affiliation with the UPMC CancerCenter network. Access to UPMC’s international experts and resources affords us the opportunity to offer our patients enhanced cancer care services close to home,” said Joseph P. Ross, Meritus Health’s president and CEO. “Service improvements, access to research studies, genetic counseling, support programs and educational resources are valuable assets for our patients, providers and staff.”

UPCI Awarded Nearly $10 Million in Prestigious NCI Grants to Foster Cancer Research

PITTSBURGH, April 24, 2014 – The University of Pittsburgh Cancer Institute (UPCI) has been awarded two highly sought-after grants from the National Cancer Institute (NCI), totaling nearly $10 million, that will aid in bringing the latest research developments from bench to bedside and accelerate research into such things as rare tumors. UPCI is one of only 12 centers in the country to receive the NCI Experimental Therapeutics-Clinical Trials Network with Phase I Emphasis grant and the only center in Pennsylvania to receive a Lead Academic Participating Site (LAPS) grant under the NCI’s new clinical trials network.

That’s good news to patients like Patrick Jackson, who was diagnosed with a rare cancer known as grade I myxopapillary-ependymomas a few years ago. Jackson was referred to UPMC, where doctors treat just a couple of cases like his each year. He said any developments that can speed research and help cancer patients is a good thing.

“I am so fortunate that my ependymoma is low grade and has responded so well to treatment,” Jackson said. “I would just want people to know that there is hope, and there is nothing more comforting than having doctors familiar with your disease.”

The awards are further evidence of UPCI’s place as one of the premier academic cancer research centers in the country. UPCI is the only NCI-designated comprehensive cancer center in western Pennsylvania and through the network of its clinical partner, UPMC CancerCenter, enables several thousand patients to participate in clinical trials each year.

“Participating in a clinical trial is the optimal form of therapy for patients who are willing and able and allows us to learn something for the future along the way. We are grateful for the support of our patients and providers who have been an integral part of our success and helped us attain these two very important awards,” said Nancy E. Davidson, M.D., director of UPCI and the UPMC CancerCenter.

The NCI Experimental Therapeutics-Clinical Trials Network with Phase I Emphasis grant is led by UPCI Deputy Director Edward Chu, M.D. The $4.25 million, five-year grant funds complex research into new drug therapies.

“Our focus is on developing completely novel agents and combination regimens. We also are trying to understand how some of these new targeted therapies work and how we can apply science to individually tailor these new treatments to specific cancers,” Dr. Chu said.

UPCI is uniquely qualified to lead efforts in drug development because of the team approach that goes into the research, he noted, with expertise in pharmacokinetics, pharmacodynamics and basic science.

“We have a large patient base that allows us to do these novel first-in-man studies. The large majority of the patients who are referred to us have failed standard-of-care therapies, and they are looking for new treatments. There is only a small handful of cancer centers across the country that can offer the types of phase I clinical studies available to our patients here in Pittsburgh and the western Pennsylvania region,” Dr. Chu said.

The LAPS grant is part of the new National Clinical Trials Network (NCTN), designed to speed up the time it takes research to get from the lab to patients through technological advances and enhanced cooperation. The nearly $5 million award is led by Adam Brufsky, M.D., Ph.D., UPCI’s associate director for clinical investigation. The grant will fund the costs of maintaining a clinical trials infrastructure that permits patients to enroll in national trials led by the NCTN at more than a dozen sites across the UPMC CancerCenter network.

“This grant is tremendous validation from the NCI about the important and cutting-edge work that we are doing here at UPCI and our ability to shape what’s happening in cancer research across the country. We’re excited to play a vital role in this new system and expand access to trials all over western Pennsylvania,” Dr. Brufsky said.

As part of the award, Dr. Brufsky will lead a group at UPCI that includes Dwight E. Heron, M.D., Mark Socinski, M.D.; John Kirkwood, M.D., and Robert P. Edwards, M.D.

The NCTN replaces the cooperative networks that existed previously and were based on a model developed more than half a century ago. NCI officials hope to speed research through improvements in data management infrastructure, the development of a standardized process for prioritization of new studies, consolidation of its component research groups to improve efficiency, and the implementation of a unified system of research subject protection at over 3,000 clinical trials sites.

One important outcome of this new network will be the ability to facilitate the conduct of trials in rare tumors where patient accrual has always been very difficult. The availability of a national network of clinical trials sites to locate and enroll patients with unusual cancers should enhance the feasibility of conducting such studies. Also, as more cancers are molecularly defined and classified into smaller subsets, the new network structure will support the molecular screening studies needed to define and locate the smaller groups of patients who might be eligible for such studies.

“It has always been our mission at UPMC CancerCenter to provide the best care possible to patients in their own communities, and this grant enhances our ability to do that,” Dr. Davidson said.

Malfunction in Molecular ‘Proofreader’ Prevents Repair of UV-Induced DNA Damage

PITTSBURGH, April 21, 2014 – Malfunctions in the molecular “proofreading” machinery, which repairs structural errors in DNA caused by ultraviolet (UV) light damage, help explain why people who have the disease xeroderma pigmentosum (XP) are at an extremely high risk for developing skin cancer, according to researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute (UPCI). Their findings will be published this week in the early online version of the Proceedings of the National Academy of Sciences.

Previous research has shown that a DNA-repair protein called human UV-damaged DNA-binding protein, or UV-DDB, signals for a repair when two UV-DDB molecules bind to the site of the problem, said senior investigator Bennett Van Houten, Ph.D., the Richard M. Cyert Professor of Molecular Oncology, Pitt School of Medicine, and co-leader of UPCI’s Molecular and Cell Biology Program.

“Our new study shows UV-DDB makes stops along the DNA strand and transiently attaches to it, causing a proofreading change in the protein’s conformation, or shape. If the DNA is damaged the protein stays, if the DNA is not damaged the protein leaves,” Dr. Van Houten said. “When it comes to a spot that has been damaged by UV radiation, two molecules of UV-DDB converge and stay tightly bound to the site, essentially flagging it for the attention of repair machinery.”

The researchers followed the trail of single molecules of UV-DDB by tagging them with light-emitting quantum dots, enabling them to watch the molecules jump from place to place in real time on both normal and UV-exposed DNA strands.

They also tracked a mutant UV-DDB protein associated with XP, an inherited, incurable disease of light sensitivity that affects about 1 in 250,000 people. They found that the mutant UV-DDB molecules are still capable of binding to DNA, but continued to slide along the DNA rather than staying put to signal where the fix was needed.

“Without this important damage control, UV-induced errors could accumulate to cause cell alterations that foster cancer development,” Dr. Van Houten said. “Like a bus with no brakes, the XP-associated UV-DDB complex stays on the road and sees possible passengers, but keeps going past the stop.”

Co-investigators include Harshad Ghodke, Ph.D., Ching L. Hsieh, Selamawit Woldemeskel, Simon C. Watkins, Ph.D., and Vesna Rapic-Otrin, Ph.D., all of the University of Pittsburgh School of Medicine; and Hong Wang, Ph.D., of North Carolina State University.

The project was funded by the University of Pittsburgh Cancer Institute Cancer Center Support grant CA 047904 and National Institutes of Health grant ES019566.

Common Breast Cancer Subtype May Benefit From Personalized Treatment Approach, UPCI Finds

SAN DIEGO, April 4, 2014 – The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by scientists at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common invasive ductal carcinoma. The results recently were published in Cancer Research and will be expanded upon on Tuesday at the American Association for Cancer Research (AACR) Annual Meeting 2014.

Patients with invasive lobular carcinoma typically are treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.

“However, recent analyses suggest that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma,” said lead author Matthew Sikora, Ph.D., postdoctoral associate at UPCI, and recipient of this year’s AACR-Susan G. Komen Scholar-in-Training Award for this research. “Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to potential targets for drug therapy in future clinical trials, which we are developing.”

Early studies in developing these potential targets are the topic of Dr. Sikora’s AACR presentation, with a focus on a unique signaling pathway regulated by estrogen specifically in lobular carcinoma cells.

Additional researchers on this study include Steffi Oesterreich, Ph.D., and Amir Bahreini, B.S., both of UPCI.

This research was supported by the Breast Cancer Research Foundation, Department of Defense Breast Cancer Research Program and Pennsylvania Department of Health.

Combining Cell Replication Blocker with Common Cancer Drug Kills Resistant Tumor Cells, UPCI Researchers Find

SAN DIEGO, April 4, 2014 – Researchers from the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, have found that an agent that inhibits mitochondrial division can overcome tumor cell resistance to a commonly used cancer drug, and that the combination of the two induces rapid and synergistic cell death. Separately, neither had an effect. These findings will be presented Monday at the annual meeting of the American Association for Cancer Research Annual Meeting 2014.

“In our earlier work, we found that blocking production of a protein called Drp1 stopped mitochondria, known as the powerhouses of the cell, from undergoing fission, which is necessary for the cellular division process called mitosis,” said Bennett Van Houten, Ph.D., the Richard M. Cyert Professor of Molecular Oncology, Pitt School of Medicine, and leader of UPCI’s Molecular and Cell Biology Program. “The loss of this critical mitochondrial protein caused the cells to arrest in mitosis and to develop chromosomal errors, and eventually led the tumor cell into the cell death pathway known as apoptosis.”

The researchers blocked Drp1 in breast cancer cell lines with an agent called mitochondrial division inhibitor-1 (mdivi-1) and found that when mdivi-1 and the cancer drug cisplatin were given together, they caused DNA damage, DNA replication stress, and greater than expected apoptosis rates. The synergistic drug combination acted through two independent biochemical pathways that caused the mitochondrial membrane to swell, increasing its permeability and allowing the leak of chemical signals that trigger apoptosis.

“Cisplatin is one of the most widely used cancer drugs today, but some tumors are inherently resistant to it, and many others become resistant, leading to treatment failure,” Dr. Van Houten said. “In our studies, this combination overcame cisplatin resistance and caused cancer cell death, which is very encouraging.”

The team is testing the regimen’s effectiveness in a mouse model of ovarian cancer, a disease that often recurs and no longer responds to cisplatin treatment.

Screening Reveals Additional Link Between Endometriosis and Ovarian Cancer

SAN DIEGO, April 4, 2014 – Some women with endometriosis, a chronic inflammatory disease, are predisposed to ovarian cancer, and a genetic screening might someday help reveal which women are most at risk, according to a University of Pittsburgh Cancer Institute (UPCI) study, in partnership with Magee-Womens Research Institute (MWRI).

Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014, UPCI and MWRI researchers will present the preliminary results of the first comprehensive immune gene profile exploring endometriosis and cancer.

“A small subset of women with endometriosis go on to develop ovarian cancer, but doctors have no clinical way to predict which women,” said senior author Anda Vlad, M.D., Ph.D., assistant professor of obstetrics, gynecology and reproductive sciences at MWRI. “If further studies show that the genetic pathway we uncovered is indicative of future cancer development, then doctors will know to more closely monitor certain women and perhaps take active preventative measures, such as immune therapy.”

Endometriosis is a painful, often invasive and recurrent condition that happens when the tissue that lines the uterus grows outside of the uterus, causing inflammation. It affects approximately one in 10 women.

By screening tissue samples from women with benign endometriosis, endometriosis with precancerous lesions and endometriosis-associated ovarian cancer, Dr. Vlad and her colleagues identified the complement pathway, which refers to a series of protein interactions that trigger an amplified immune response, as the most prominent immune pathway that is activated in both endometriosis and endometriosis-associated ovarian cancer.

“If, as our study indicates, a problem with the immune system facilitates cancer growth through chronic activation of the complement pathway, then perhaps we can find ways to change that and more effectively prime immune cells to fight early cancer, while controlling the complement pathway,” said lead author Swati Maruti Suryawanshi, Ph.D., a post-doctoral research fellow at MWRI.

Instrumental to this multidisciplinary study were Robert P. Edwards, M.D., and Esther Elishaev, M.D., both of Magee-Womens Hospital of UPMC, and Xin Huang, Ph.D., MWRI. Additional contributors are Raluca Budiu, Ph.D., SungHwan Kim, Ph.D., and George Tseng, Ph.D., all of Pitt; and Marcia Klein-Patel, M.D., Ted Lee, M.D., Suketu Mansuria, M.D., all of UPMC.

This research was funded by UPMC grant 02.93530.

Page 1 of 8:1 2 3 4 »Last »